

Umberto Malapelle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8718416/publications.pdf>

Version: 2024-02-01

244
papers

6,119
citations

66234

42
h-index

123241

61
g-index

249
all docs

249
docs citations

249
times ranked

6622
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1647-1662. | 0.5 | 274 |
| 2 | Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 209-215. | 1.5 | 135 |
| 3 | CBX7 is a tumor suppressor in mice and humans. <i>Journal of Clinical Investigation</i> , 2012, 122, 612-623. | 3.9 | 133 |
| 4 | Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients. <i>British Journal of Cancer</i> , 2017, 116, 802-810. | 2.9 | 124 |
| 5 | The evolving landscape of biomarker testing for non-small cell lung cancer in Europe. <i>Lung Cancer</i> , 2021, 154, 161-175. | 0.9 | 105 |
| 6 | SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 4686-4697. | 3.2 | 103 |
| 7 | EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 51-69. | 12.5 | 101 |
| 8 | The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal. <i>Cancer Treatment Reviews</i> , 2020, 85, 101994. | 3.4 | 89 |
| 9 | Next generation sequencing techniques in liquid biopsy: focus on non-small cell lung cancer patients. <i>Translational Lung Cancer Research</i> , 2016, 5, 505-510. | 1.3 | 88 |
| 10 | Sphingosine Kinase 1 Overexpression Contributes to Cetuximab Resistance in Human Colorectal Cancer Models. <i>Clinical Cancer Research</i> , 2013, 19, 138-147. | 3.2 | 87 |
| 11 | Ion Torrent next-generation sequencing for routine identification of clinically relevant mutations in colorectal cancer patients. <i>Journal of Clinical Pathology</i> , 2015, 68, 64-68. | 1.0 | 81 |
| 12 | Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB). <i>Critical Reviews in Oncology/Hematology</i> , 2020, 151, 102978. | 2.0 | 79 |
| 13 | Challenges and opportunities of next-generation sequencing: a cytopathologist's perspective. <i>Cytopathology</i> , 2015, 26, 271-283. | 0.4 | 76 |
| 14 | Next-Generation Sequencing of Lung Cancer EGFR Exons 18-21 Allows Effective Molecular Diagnosis of Small Routine Samples (Cytology and Biopsy). <i>PLoS ONE</i> , 2013, 8, e83607. | 1.1 | 76 |
| 15 | Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases. <i>Journal of Clinical Pathology</i> , 2016, 69, 767-771. | 1.0 | 75 |
| 16 | Liquid Biopsy and Lung Cancer. <i>Acta Cytologica</i> , 2019, 63, 489-496. | 0.7 | 75 |
| 17 | The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials. <i>ESMO Open</i> , 2021, 6, 100124. | 2.0 | 75 |
| 18 | EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients. <i>Cancer Cytopathology</i> , 2013, 121, 552-560. | 1.4 | 71 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | How to prepare cytological samples for molecular testing. <i>Journal of Clinical Pathology</i> , 2017, 70, 819-826. | 1.0 | 70 |
| 20 | PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 644737. | 1.3 | 70 |
| 21 | Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions. <i>Molecular Oncology</i> , 2019, 13, 2633-2645. | 2.1 | 69 |
| 22 | The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOMâ€“SIAPEC-IAPâ€“SIBioCâ€“SICâ€“SIF Italian Scientific Societies. <i>ESMO Open</i> , 2021, 6, 100164. | 2.0 | 69 |
| 23 | EGFR and KRAS mutations detection on lung cancer liquid-based cytology: a pilot study. <i>Journal of Clinical Pathology</i> , 2012, 65, 87-91. | 1.0 | 67 |
| 24 | Class 1, 2, and 3 <i>BRAF</i> -Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization. <i>Clinical Cancer Research</i> , 2019, 25, 3954-3961. | 3.2 | 67 |
| 25 | PTEN Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine?. <i>Genes</i> , 2020, 11, 719. | 1.0 | 67 |
| 26 | Next Generation Sequencing and Genetic Alterations in Squamous Cell Lung Carcinoma: Where Are We Today?. <i>Frontiers in Oncology</i> , 2019, 9, 166. | 1.3 | 61 |
| 27 | Noninvasive Biomarkers of Colorectal Cancer: Role in Diagnosis and Personalised Treatment Perspectives. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-21. | 0.7 | 60 |
| 28 | Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens. <i>Cancer Cytopathology</i> , 2017, 125, 615-626. | 1.4 | 58 |
| 29 | Immunotherapy in non-small cell lung cancer harbouring driver mutations. <i>Cancer Treatment Reviews</i> , 2021, 96, 102179. | 3.4 | 56 |
| 30 | Evaluation of <i>BRAF</i> , <i>RAS</i> , <i>RET/PTC</i> , and <i>PAX8/PPARg</i> alterations in different Bethesda diagnostic categories: A multicentric prospective study on the validity of the 7-gene panel test in 1172 thyroid FNAs deriving from different hospitals in South Italy. <i>Cancer Cytopathology</i> , 2020, 128, 107-118. | 1.4 | 55 |
| 31 | Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: A review. <i>Diagnostic Cytopathology</i> , 2011, 39, 703-710. | 0.5 | 54 |
| 32 | Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5452. | 1.8 | 53 |
| 33 | Precision Prevention and Cancer Interception: The New Challenges of Liquid Biopsy. <i>Cancer Discovery</i> , 2020, 10, 1635-1644. | 7.7 | 52 |
| 34 | USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugs. <i>Lung Cancer</i> , 2017, 107, 41-49. | 0.9 | 51 |
| 35 | Cytopathologists can reliably perform ultrasound-guided thyroid fine needle aspiration: a 1-year audit on 3715 consecutive cases. <i>Cytopathology</i> , 2016, 27, 115-121. | 0.4 | 50 |
| 36 | Liquid biopsy tracking of lung tumor evolutions over time. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 1099-1108. | 1.5 | 50 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Analysis of Differential miRNA Expression in Primary Tumor and Stroma of Colorectal Cancer Patients. <i>BioMed Research International</i> , 2014, 2014, 1-8. | 0.9 | 49 |
| 38 | Targeting immune checkpoints in non small cell lung cancer. <i>Current Opinion in Pharmacology</i> , 2018, 40, 46-50. | 1.7 | 49 |
| 39 | Cytology in the time of coronavirus disease (COVID-19): an Italian perspective. <i>Journal of Clinical Pathology</i> , 2021, 74, 261-263. | 1.0 | 49 |
| 40 | KRAS mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal setting. <i>Journal of Thoracic Disease</i> , 2020, 12, 3836-3843. | 0.6 | 47 |
| 41 | Global impact of the COVID-19 pandemic on cytopathology practice: Results from an international survey of laboratories in 23 countries. <i>Cancer Cytopathology</i> , 2020, 128, 885-894. | 1.4 | 47 |
| 42 | The Role of the Pathologist in the Next-Generation Era of Tumor Molecular Characterization. <i>Diagnostics</i> , 2021, 11, 339. | 1.3 | 46 |
| 43 | EGFR mutation detection on lung cancer cytological specimens by the novel fully automated PCR-based Idylla EGFR Mutation Assay. <i>Journal of Clinical Pathology</i> , 2017, 70, 295-300. | 1.0 | 44 |
| 44 | ALK and ROS1 testing on lung cancer cytologic samples: Perspectives. <i>Cancer Cytopathology</i> , 2017, 125, 817-830. | 1.4 | 44 |
| 45 | Prognostic Factors and Biomarkers of Responses to Immune Checkpoint Inhibitors in Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4931. | 1.8 | 44 |
| 46 | Liquid Biopsy in Prostate Cancer Management—Current Challenges and Future Perspectives. <i>Cancers</i> , 2022, 14, 3272. | 1.7 | 44 |
| 47 | An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 35-45. | 1.5 | 42 |
| 48 | The Treatment of Advanced Melanoma: Therapeutic Update. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6388. | 1.8 | 41 |
| 49 | Applications and limitations of oncogene mutation testing in clinical cytopathology. <i>Seminars in Diagnostic Pathology</i> , 2013, 30, 284-297. | 1.0 | 40 |
| 50 | The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM-SIAPEC/IAP-SiBioC-SIF Italian Scientific Societies. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 165, 103436. | 2.0 | 40 |
| 51 | Cell free DNA analysis by SiRe® next generation sequencing panel in non small cell lung cancer patients: focus on basal setting. <i>Journal of Thoracic Disease</i> , 2017, 9, S1383-S1390. | 0.6 | 39 |
| 52 | Consistency and reproducibility of next-generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens. <i>Cancer Cytopathology</i> , 2019, 127, 285-296. | 1.4 | 39 |
| 53 | Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical) Tj ETQq1 1 0.784314 rgBT /Overlo | 2.0 | 39 |
| 54 | A BRAF new world. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 152, 103008. | 2.0 | 39 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Next generation sequencing in cytology. <i>Cytopathology</i> , 2021, 32, 588-595. | 0.4 | 39 |
| 56 | Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2625. | 1.8 | 38 |
| 57 | Cytological and Molecular Features of Papillary Thyroid Carcinoma with Prominent Hobnail Features: A Case Report. <i>Acta Cytologica</i> , 2012, 56, 560-564. | 0.7 | 37 |
| 58 | Epidermal Growth Factor Receptor Test Performed on Liquid-Based Cytology Lung Samples: Experience of an Academic Referral Center. <i>Acta Cytologica</i> , 2014, 58, 589-594. | 0.7 | 37 |
| 59 | Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker. <i>BioMed Research International</i> , 2019, 2019, 1-15. | 0.9 | 37 |
| 60 | Performance analysis of SiRe next-generation sequencing panel in diagnostic setting: focus on NSCLC routine samples. <i>Journal of Clinical Pathology</i> , 2019, 72, 38-45. | 1.0 | 37 |
| 61 | EGFR analysis: Current evidence and future directions. <i>Diagnostic Cytopathology</i> , 2014, 42, 984-992. | 0.5 | 36 |
| 62 | The Promise of Digital Biopsy for the Prediction of Tumor Molecular Features and Clinical Outcomes Associated With Immunotherapy. <i>Frontiers in Medicine</i> , 2019, 6, 172. | 1.2 | 36 |
| 63 | Cyclin D1 and D3 overexpression predicts malignant behavior in thyroid fine-needle aspirates suspicious for Hurthle cell neoplasms. <i>Cancer Cytopathology</i> , 2009, 117, 522-529. | 1.4 | 34 |
| 64 | Tumor mutational burden on cytological samples: A pilot study. <i>Cancer Cytopathology</i> , 2021, 129, 460-467. | 1.4 | 34 |
| 65 | EGFR mutations detection on liquid-based cytology: is microscopy still necessary?. <i>Journal of Clinical Pathology</i> , 2012, 65, 561-564. | 1.0 | 33 |
| 66 | Different qualifiers of AUS/FLUS thyroid FNA have distinct <i>BRAF</i> , <i>RAS</i> , <i>RET</i> / <i>PTC</i> , and <i>PAX8</i> / <i>PPARg</i> alterations. <i>Cancer Cytopathology</i> , 2018, 126, 317-325. | 1.4 | 33 |
| 67 | Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR. <i>Oncotarget</i> , 2017, 8, 23020-23032. | 0.8 | 33 |
| 68 | Idylla assay and next generation sequencing: an integrated EGFR mutational testing algorithm. <i>Journal of Clinical Pathology</i> , 2018, 71, 745-750. | 1.0 | 32 |
| 69 | Understanding EGFR heterogeneity in lung cancer. <i>ESMO Open</i> , 2020, 5, e000919. | 2.0 | 32 |
| 70 | Evaluation of Micro Satellite Instability and Mismatch Repair Status in Different Solid Tumors: A Multicenter Analysis in a Real World Setting. <i>Cells</i> , 2021, 10, 1878. | 1.8 | 32 |
| 71 | Next generation diagnostic algorithm in non-small cell lung cancer predictive molecular pathology: The KWAY Italian multicenter cost evaluation study. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103525. | 2.0 | 32 |
| 72 | Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario. <i>ESMO Open</i> , 2022, 7, 100406. | 2.0 | 31 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | KRAS testing in metastatic colorectal carcinoma: challenges, controversies, breakthroughs and beyond. <i>Journal of Clinical Pathology</i> , 2014, 67, 1-9. | 1.0 | 30 |
| 74 | Outsourcing cytological samples to a referral laboratory for <scp>EGFR</scp> testing in nonâ€small cell lung cancer: does theory meet practice?. <i>Cytopathology</i> , 2015, 26, 312-317. | 0.4 | 30 |
| 75 | EGFR T790M detection rate in lung adenocarcinomas at baseline using droplet digital PCR and validation by ultra-deep next generation sequencing. <i>Translational Lung Cancer Research</i> , 2019, 8, 584-592. | 1.3 | 30 |
| 76 | KRAS inhibition in nonâ€small cell lung cancer: Past failures, new findings and upcoming challenges. <i>European Journal of Cancer</i> , 2020, 137, 57-68. | 1.3 | 30 |
| 77 | Impact of Pre-Analytical Factors on MSI Test Accuracy in Mucinous Colorectal Adenocarcinoma: A Multi-Assay Concordance Study. <i>Cells</i> , 2020, 9, 2019. | 1.8 | 30 |
| 78 | Thyroid cytology smear slides: An untapped resource for ThyroSeq testing. <i>Cancer Cytopathology</i> , 2021, 129, 33-42. | 1.4 | 30 |
| 79 | Sanger sequencing in routine KRAS testing: a review of 1720 cases from a pathologist's perspective. <i>Journal of Clinical Pathology</i> , 2012, 65, 940-944. | 1.0 | 29 |
| 80 | Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models. <i>Journal of Thoracic Oncology</i> , 2018, 13, 810-820. | 0.5 | 29 |
| 81 | RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients. <i>European Journal of Cancer</i> , 2021, 146, 74-83. | 1.3 | 29 |
| 82 | Fully automated PCR detection of KRAS mutations on pancreatic endoscopic ultrasound fine-needle aspirates. <i>Journal of Clinical Pathology</i> , 2016, 69, 986-991. | 1.0 | 28 |
| 83 | PD-L1 evaluation in head and neck squamous cell carcinoma: Insights regarding specimens, heterogeneity and therapy. <i>Pathology Research and Practice</i> , 2021, 226, 153605. | 1.0 | 28 |
| 84 | UbcH10 overexpression in human lung carcinomas and its correlation with EGFR and p53 mutational status. <i>European Journal of Cancer</i> , 2013, 49, 1117-1126. | 1.3 | 27 |
| 85 | Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2021, 39, 2574-2585. | 0.8 | 27 |
| 86 | Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence. <i>Current Oncology</i> , 2022, 29, 255-266. | 0.9 | 27 |
| 87 | PD-L1 expression on routine samples of non-small cell lung cancer: results and critical issues from a 1-year experience of a centralised laboratory. <i>Journal of Clinical Pathology</i> , 2019, 72, 412-417. | 1.0 | 26 |
| 88 | Next Generation Sequencing in Cytopathology: Focus on Non-Small Cell Lung Cancer. <i>Frontiers in Medicine</i> , 2021, 8, 633923. | 1.2 | 26 |
| 89 | Evidenceâ€based diagnostic performance of novel biomarkers for the diagnosis of malignant mesothelioma in effusion cytology. <i>Cancer Cytopathology</i> , 2022, 130, 96-109. | 1.4 | 26 |
| 90 | The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103567. | 2.0 | 26 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies. <i>ESMO Open</i> , 2022, 7, 100459. | 2.0 | 26 |
| 92 | Immunoglobulin heavy chain fluorescence in situ hybridization chromogenic in situ hybridization DNA probe split signal in the clonality assessment of lymphoproliferative processes on cytological samples. <i>Cancer Cytopathology</i> , 2012, 120, 390-400. | 1.4 | 25 |
| 93 | Immunotherapy in Breast Cancer Patients: A Focus on the Use of the Currently Available Biomarkers in Oncology. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 787-800. | 0.9 | 25 |
| 94 | KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2012, 107, 626-631. | 2.9 | 24 |
| 95 | Osimertinib. <i>Recent Results in Cancer Research</i> , 2018, 211, 257-276. | 1.8 | 24 |
| 96 | Next generation sequencing for liquid biopsy based testing in non-small cell lung cancer in 2021. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 161, 103311. | 2.0 | 24 |
| 97 | Metastasis of colon cancer to the thyroid gland: A case diagnosed on fine needle aspirate by a combined cytological, immunocytochemical, and molecular approach. <i>Diagnostic Cytopathology</i> , 2010, 38, 932-935. | 0.5 | 23 |
| 98 | Lung adenocarcinoma and its thyroid metastasis characterized on fine needle aspirates by cytomorphology, immunocytochemistry, and next generation sequencing. <i>Diagnostic Cytopathology</i> , 2015, 43, 585-589. | 0.5 | 23 |
| 99 | Restoration of CBX7 expression increases the susceptibility of human lung carcinoma cells to irinotecan treatment. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2015, 388, 1179-1186. | 1.4 | 23 |
| 100 | BRAF: A Two-Faced Janus. <i>Cells</i> , 2020, 9, 2549. | 1.8 | 23 |
| 101 | EGFR mutation detection on routine cytological smears of non-small cell lung cancer by digital PCR: a validation study. <i>Journal of Clinical Pathology</i> , 2016, 69, 454-457. | 1.0 | 22 |
| 102 | miR-155 is positively regulated by CBX7 in mouse embryonic fibroblasts and colon carcinomas, and targets the KRAS oncogene. <i>BMC Cancer</i> , 2017, 17, 170. | 1.1 | 22 |
| 103 | UbcH10 expression can predict prognosis and sensitivity to the antineoplastic treatment for colorectal cancer patients. <i>Molecular Carcinogenesis</i> , 2016, 55, 793-807. | 1.3 | 21 |
| 104 | Young investigator challenge: Can the Ion AmpliSeq Cancer Hotspot Panel v2 be used for next generation sequencing of thyroid FNA samples?. <i>Cancer Cytopathology</i> , 2016, 124, 776-784. | 1.4 | 21 |
| 105 | KRAS mutation analysis on cytological specimens of metastatic colorectal cancer. <i>Diagnostic Cytopathology</i> , 2010, 38, 869-873. | 0.5 | 20 |
| 106 | KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy. <i>Oncotarget</i> , 2018, 9, 26279-26290. | 0.8 | 20 |
| 107 | The Reproducibility of the Immunohistochemical PD-L1 Testing in Non-Small-Cell Lung Cancer: A Multicentric Italian Experience. <i>BioMed Research International</i> , 2019, 2019, 1-7. | 0.9 | 20 |
| 108 | Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 1165-1178. | 1.5 | 20 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Preparation of thyroid FNA material for routine cytology and BRAF testing: A validation study. <i>Diagnostic Cytopathology</i> , 2010, 38, 172-176. | 0.5 | 19 |
| 110 | Cytological and molecular diagnosis of solid variant of papillary thyroid carcinoma: A case report. <i>CytoJournal</i> , 2008, 5, 2. | 0.8 | 19 |
| 111 | EML4-ALK translocation identification in RNA exosomal cargo (ExoALK) in NSCLC patients: a novel role for liquid biopsy. <i>Translational Cancer Research</i> , 2018, 8, S76-S78. | 0.4 | 19 |
| 112 | Liquid Biopsy for Biomarker Testing in Non-Small Cell Lung Cancer: A European Perspective. <i>Journal of Molecular Pathology</i> , 2021, 2, 255-273. | 0.5 | 18 |
| 113 | PAX8 is expressed in anaplastic thyroid carcinoma diagnosed by fine-needle aspiration: a study of three cases with histological correlates. <i>European Journal of Endocrinology</i> , 2013, 169, 307-311. | 1.9 | 17 |
| 114 | BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 156, 103118. | 2.0 | 17 |
| 115 | Predictive molecular pathology in the time of coronavirus disease (COVID-19) in Europe. <i>Journal of Clinical Pathology</i> , 2021, 74, 391-395. | 1.0 | 17 |
| 116 | RNA-Based Assay for Next-Generation Sequencing of Clinically Relevant Gene Fusions in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 139. | 1.7 | 17 |
| 117 | Small Cell Lung Cancer: State of the Art of the Molecular and Genetic Landscape and Novel Perspective. <i>Cancers</i> , 2021, 13, 1723. | 1.7 | 17 |
| 118 | There is still a role for cytology in the "liquid biopsy"™ era. A lesson from a TKI-treated patient showing adenocarcinoma to squamous cell carcinoma transition during disease progression. <i>Journal of Clinical Pathology</i> , 2017, 70, 798-802. | 1.0 | 16 |
| 119 | New perspectives in the second-line treatment of non squamous NSCLC patients: Results from a large Italian Lung Cancer Working Group. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 109, 35-41. | 2.0 | 16 |
| 120 | Rapid On-site Molecular Evaluation in thyroid cytopathology: A same-day cytological and molecular diagnosis. <i>Diagnostic Cytopathology</i> , 2020, 48, 300-307. | 0.5 | 16 |
| 121 | The storm of NGS in NSCLC diagnostic-therapeutic pathway: How to sun the real clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103561. | 2.0 | 16 |
| 122 | A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal Cancer. <i>Cancers</i> , 2019, 11, 147. | 1.7 | 15 |
| 123 | Cytopathology practice during the COVID-19 postlockdown: An Italian experience. <i>Cancer Cytopathology</i> , 2021, 129, 548-554. | 1.4 | 15 |
| 124 | EGFR exon 19 deletion switch and development of p.L792Q mutation as a new resistance mechanism to osimertinib: a case report and literature review. <i>Translational Cancer Research</i> , 2018, 8, S64-S69. | 0.4 | 15 |
| 125 | COVID-19 pandemic impact on cytopathology practice in the post-lockdown period: An international, multicenter study. <i>Cancer Cytopathology</i> , 2022, 130, 344-351. | 1.4 | 15 |
| 126 | Is the Idylla <i>EGFR</i> Mutation Assay feasible on archival stained cytological smears? A pilot study. <i>Journal of Clinical Pathology</i> , 2019, 72, 609-614. | 1.0 | 14 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | KRAS Mutant Allele-Specific Imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer. <i>Journal of Clinical Pathology</i> , 2015, 68, 265-269. | 1.0 | 13 |
| 128 | Multiplex digital colour-coded barcode technology on RNA extracted from routine cytological samples of patients with non-small cell lung cancer: pilot study. <i>Journal of Clinical Pathology</i> , 2017, 70, 803-806. | 1.0 | 13 |
| 129 | Targeting emerging molecular alterations in the treatment of non-small cell lung cancer: current challenges and the way forward. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 363-372. | 1.9 | 13 |
| 130 | Predictive molecular pathology in the time of COVID-19. <i>Journal of Clinical Pathology</i> , 2021, 74, 234-237. | 1.0 | 13 |
| 131 | Thyroid fine-needle aspiration trends before, during, and after the lockdown: what we have learned so far from the COVID-19 pandemic. <i>Endocrine</i> , 2021, 71, 20-25. | 1.1 | 13 |
| 132 | FFPE-Based NGS Approaches into Clinical Practice: The Limits of Glory from a Pathologist Viewpoint. <i>Journal of Personalized Medicine</i> , 2022, 12, 750. | 1.1 | 13 |
| 133 | Multicentric encapsulated papillary oncocytic neoplasm of the thyroid: A case diagnosed by a combined cytological, histological, immunohistochemical, and molecular approach. <i>Diagnostic Cytopathology</i> , 2012, 40, 450-454. | 0.5 | 12 |
| 134 | EGFR mutation detection by microfluidic technology: a validation study. <i>Journal of Clinical Pathology</i> , 2013, 66, 982-984. | 1.0 | 12 |
| 135 | Lung Cancer in Italy. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2046-2052. | 0.5 | 12 |
| 136 | Clinical Multigene Panel Sequencing Identifies Distinct Mutational Association Patterns in Metastatic Colorectal Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 560. | 1.3 | 12 |
| 137 | Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record. <i>Cancers</i> , 2020, 12, 1800. | 1.7 | 12 |
| 138 | KRAS testing on colorectal carcinoma cytological imprints. <i>Diagnostic Cytopathology</i> , 2011, 39, 274-277. | 0.5 | 11 |
| 139 | Foamy gland pancreatic ductal adenocarcinoma diagnosed on EUS-FNA: A histochemical, immunohistochemical, and molecular report. <i>Diagnostic Cytopathology</i> , 2013, 41, 77-80. | 0.5 | 11 |
| 140 | Microsatellite instability evaluation by automated microfluidic electrophoresis: an update. <i>Journal of Clinical Pathology</i> , 2017, 70, 90.2-91. | 1.0 | 11 |
| 141 | Harmonization of Next-Generation Sequencing Procedure in Italian Laboratories: A Multi-Institutional Evaluation of the SiRe® Panel. <i>Frontiers in Oncology</i> , 2020, 10, 236. | 1.3 | 11 |
| 142 | PD-L1 and beyond: Immunooncology in cytopathology. <i>Cytopathology</i> , 2021, 32, 596-603. | 0.4 | 11 |
| 143 | p.G12C KRAS mutation prevalence in non-small cell lung cancer: Contribution from interregional variability and population substructures among Hispanics. <i>Translational Oncology</i> , 2022, 15, 101276. | 1.7 | 11 |
| 144 | The Cause of Death of a Child in the 18th Century Solved by Bone Microbiome Typing Using Laser Microdissection and Next Generation Sequencing. <i>International Journal of Molecular Sciences</i> , 2017, 18, 109. | 1.8 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Emerging angiogenesis inhibitors for non-small cell lung cancer. <i>Expert Opinion on Emerging Drugs</i> , 2019, 24, 71-81. | 1.0 | 10 |
| 146 | Targeting KRAS in NSCLC: Old Failures and New Options for “Non-G12c” Patients. <i>Cancers</i> , 2021, 13, 6332. | 1.7 | 10 |
| 147 | p53 expression in cell blocks of non-small cell lung cancer: The impact of prolonged fixation. <i>Diagnostic Cytopathology</i> , 2020, 48, 595-603. | 0.5 | 9 |
| 148 | Reference standards for gene fusion molecular assays on cytological samples: an international validation study. <i>Journal of Clinical Pathology</i> , 2023, 76, 47-52. | 1.0 | 9 |
| 149 | Next generation sequencing identifies novel potential actionable mutations for grade I meningioma treatment. <i>Histology and Histopathology</i> , 2020, 35, 741-749. | 0.5 | 9 |
| 150 | KRAS detection on archival cytological smears by the novel fully automated polymerase chain reaction-based Idylla mutation test. <i>CytoJournal</i> , 2017, 14, 5. | 0.8 | 9 |
| 151 | BRAF Mutations in Lung Cancer. <i>Acta Cytologica</i> , 2019, 63, 247-250. | 0.7 | 8 |
| 152 | Next-Generation Sequencing in Tumor Diagnosis and Treatment. <i>Diagnostics</i> , 2020, 10, 962. | 1.3 | 8 |
| 153 | Case Report: BAP1 Mutation and RAD21 Amplification as Predictive Biomarkers to PARP Inhibitor in Metastatic Intrahepatic Cholangiocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 567289. | 1.3 | 8 |
| 154 | Liquid biopsy for BRAF mutations testing in non-small cell lung cancer: a retrospective study. <i>Journal of Clinical Pathology</i> , 2020, , jclinpath-2020-207107. | 1.0 | 8 |
| 155 | Liquid Biopsy Is a Promising Tool for Genetic Testing in Idiopathic Pulmonary Fibrosis. <i>Diagnostics</i> , 2021, 11, 1202. | 1.3 | 8 |
| 156 | Diffuse Large B-Cell Extranodal Lymphoma of the Uterine Cervix. <i>Diagnostic Cytopathology</i> , 2014, 42, 644-646. | 0.5 | 7 |
| 157 | Next-generation sequencing in the genomic profiling of synchronous colonic carcinomas: comment on Li et al (2015). <i>Journal of Clinical Pathology</i> , 2015, 68, 946-947. | 1.0 | 7 |
| 158 | Performance of EGFR mutant-specific antibodies in different cytological preparations: a validation study. <i>Cytopathology</i> , 2015, 26, 99-105. | 0.4 | 7 |
| 159 | Evaluation of a novel liquid biopsy-based ColoScape assay for mutational analysis of colorectal neoplasia and triage of FIT+ patients: a pilot study. <i>Journal of Clinical Pathology</i> , 2018, 71, 1123-1126. | 1.0 | 7 |
| 160 | Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591984642. | 1.4 | 7 |
| 161 | Liquid biopsy as a follow-up tool: Comment on longitudinal monitoring of somatic genetic alterations in circulating cell-free DNA during treatment with epidermal growth factor receptor “tyrosine kinase inhibitors. <i>Cancer</i> , 2020, 126, 22-25. | 2.0 | 7 |
| 162 | Predictive biomarkers for molecular pathology in lung cancer. <i>Biomarkers in Medicine</i> , 2020, 14, 253-257. | 0.6 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | Circulating tumor DNA in cancer: Predictive molecular pathology meets mathematics. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103394. | 2.0 | 7 |
| 164 | EGFR mutant allelic-specific imbalance assessment in routine samples of non-small cell lung cancer. <i>Journal of Clinical Pathology</i> , 2015, 68, 739-741. | 1.0 | 6 |
| 165 | USP11 role in colorectal cancer growing and metastatisation. <i>EBioMedicine</i> , 2019, 48, 5-6. | 2.7 | 6 |
| 166 | Overcoming resistance to osimertinib in non-small cell lung cancer: Hopes, doubts, and in-between. <i>Cancer</i> , 2020, 126, 2594-2596. | 2.0 | 6 |
| 167 | Moving towards a local testing solution for undetermined thyroid fine-needle aspirates: validation of a novel custom DNA-based NGS panel. <i>Journal of Clinical Pathology</i> , 2022, 75, 465-471. | 1.0 | 6 |
| 168 | Performance evaluation of a fully closed real-time PCR platform for the detection of KRAS p.G12C mutations in liquid biopsy of patients with non-small cell lung cancer. <i>Journal of Clinical Pathology</i> , 2022, 75, 350-353. | 1.0 | 6 |
| 169 | Evaluation of a fully closed real time PCR platform for the detection of SARS-CoV-2 in nasopharyngeal swabs: a pilot study. <i>Journal of Clinical Pathology</i> , 2022, 75, 551-554. | 1.0 | 6 |
| 170 | Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 160, 103300. | 2.0 | 6 |
| 171 | Liquid Biopsy Analysis in Clinical Practice: Focus on Lung Cancer. <i>Journal of Molecular Pathology</i> , 2021, 2, 241-254. | 0.5 | 6 |
| 172 | TargetPlex FFPE-Direct DNA Library Preparation Kit for SiRe NGS panel: an international performance evaluation study. <i>Journal of Clinical Pathology</i> , 2022, 75, 416-421. | 1.0 | 6 |
| 173 | Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103536. | 2.0 | 6 |
| 174 | Microsatellite Instable Colorectal Adenocarcinoma Diagnostics: The Advent of Liquid Biopsy Approaches. <i>Frontiers in Oncology</i> , 0, 12, . | 1.3 | 6 |
| 175 | P2.01-093 Exo-ALK Proof of Concept: Exosomal Analysis of ALK Alterations in Advanced NSCLC Patients. <i>Journal of Thoracic Oncology</i> , 2017, 12, S844-S845. | 0.5 | 5 |
| 176 | Detection of epidermal growth factor receptor mutations in circulating tumor DNA: reviewing BENEFIT clinical trial. <i>Journal of Thoracic Disease</i> , 2018, 10, 6388-6391. | 0.6 | 5 |
| 177 | Circulating Tumour Cells in Predictive Molecular Pathology: Focus on Drug-Sensitive Assays and 3D Culture. <i>Acta Cytologica</i> , 2019, 63, 171-181. | 0.7 | 5 |
| 178 | Setting up and exploitation of a nano/technological platform for the evaluation of HMGA1b protein in peripheral blood of cancer patients. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019, 15, 231-242. | 1.7 | 5 |
| 179 | SARS-CoV-2 Infection in Cancer Patients: A Picture of an Italian Onco-Covid Unit. <i>Frontiers in Oncology</i> , 2020, 10, 1722. | 1.3 | 5 |
| 180 | Pharmacodynamics of current and emerging PD-1 and PD-L1 inhibitors for the treatment of non-small cell lung cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 87-96. | 1.5 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 181 | Editorial: Emerging Biomarkers for NSCLC: Recent Advances in Diagnosis and Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 694578. | 1.3 | 5 |
| 182 | Diagnostic and prognostic biomarkers in oligometastatic non-small cell lung cancer: a literature review. <i>Translational Lung Cancer Research</i> , 2021, 10, 3385-3400. | 1.3 | 5 |
| 183 | Immunotherapy in Lung Cancer: Are the Promises of Long-Term Benefit Finally Met?. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 113-142. | 0.8 | 5 |
| 184 | MMR profile and microsatellite instability status in colorectal mucinous adenocarcinoma with synchronous metastasis: a new clue for the clinical practice. <i>Journal of Clinical Pathology</i> , 2023, 76, 492-496. | 1.0 | 5 |
| 185 | Role of Cytomorphology in the Era of Liquid Biopsy. <i>Acta Cytologica</i> , 2019, 63, 497-505. | 0.7 | 4 |
| 186 | Multi-gene custom panels for the characterisation of metastatic colorectal carcinoma in clinical practice: express the role of PIK3CA mutations. <i>Journal of Clinical Pathology</i> , 2022, 75, 488-492. | 1.0 | 4 |
| 187 | The role of molecular heterogeneity targeting resistance mechanisms to lung cancer therapies. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 757-766. | 1.5 | 4 |
| 188 | ctDNA analysis in the personalized clinical management of gastroesophageal adenocarcinoma: turning hope into reality. <i>Future Oncology</i> , 2021, 17, 4607-4618. | 1.1 | 4 |
| 189 | Methods for actionable gene fusion detection in lung cancer: now and in the future. <i>Pharmacogenomics</i> , 2021, 22, 833-847. | 0.6 | 4 |
| 190 | How clinically useful is comprehensive genomic profiling for patients with non-small cell lung cancer? A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 166, 103459. | 2.0 | 4 |
| 191 | Clinico-pathological and molecular characterisation of BRAF mutant metastatic colorectal cancer (mCRC): Are all mutations created equal?. <i>Journal of Clinical Oncology</i> , 2018, 36, 3590-3590. | 0.8 | 4 |
| 192 | Warthin Tumor with Signet-Ring Cell Features as a Pitfall in Salivary Gland Cytopathology. <i>Acta Cytologica</i> , 2013, 57, 309-312. | 0.7 | 3 |
| 193 | UbcH10 overexpression is less pronounced in older colorectal cancer patients. <i>International Journal of Colorectal Disease</i> , 2016, 31, 1367-1368. | 1.0 | 3 |
| 194 | Bird's eye view of modern cytopathology: Report from the seventh international Molecular Cytopathology Meeting in Naples, Italy, 2018. <i>Cancer Cytopathology</i> , 2019, 127, 350-357. | 1.4 | 3 |
| 195 | Microfluidic chip technology applied to fine needle aspiration cytology samples for IGH clonality assessment. <i>Diagnostic Cytopathology</i> , 2019, 47, 749-757. | 0.5 | 3 |
| 196 | Reliability and reproducibility among different platforms for tumour BRCA testing in ovarian cancer: a study of the Italian NGS Network. <i>Journal of Clinical Pathology</i> , 2020, 74, jclinpath-2020-206800. | 1.0 | 3 |
| 197 | Biomarkers predictive value in early stage non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 956-959. | 1.3 | 3 |
| 198 | A narrative review of lung cancer cytology in the times of coronavirus: what physicians should know. <i>Translational Lung Cancer Research</i> , 2020, 9, 2074-2081. | 1.3 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 199 | Cytology meets next generation sequencing and liquid biopsy: A case of lung adenocarcinoma presenting as metastasis to the phalanx. <i>Diagnostic Cytopathology</i> , 2020, 48, 759-764. | 0.5 | 3 |
| 200 | Molecular profiling of advanced non-small cell lung cancer in the era of immunotherapy approach: a multicenter Italian observational prospective study of biomarker screening in daily clinical practice. <i>Journal of Clinical Pathology</i> , 2021, , jclinpath-2020-207339. | 1.0 | 3 |
| 201 | Cytopathology meets basic science. <i>Cancer Cytopathology</i> , 2015, 123, 571-572. | 1.4 | 2 |
| 202 | Discordance in RAS Mutations between Primary Colon Tumor and Metastases: A Real Event or a Matter of Methodology?. <i>International Journal of Biological Markers</i> , 2017, 32, 474-477. | 0.7 | 2 |
| 203 | Cytology versus histology for programmed death-ligand 1 expression evaluation in the landscape of non-small cell lung cancer patients selection for immunotherapy. <i>Translational Lung Cancer Research</i> , 2018, 7, S221-S224. | 1.3 | 2 |
| 204 | Relationship between performance status or younger age and osimertinib therapy in T790M-positive NSCLC: are the available data convincing?. <i>Journal of Thoracic Disease</i> , 2019, 11, S1837-S1840. | 0.6 | 2 |
| 205 | Molecular predictive testing in precision oncology: The Italian experience. <i>Cancer Cytopathology</i> , 2020, 128, 622-628. | 1.4 | 2 |
| 206 | Cytopathology Practice in the COVID-19 Era: Focus on Sample Workload. <i>Journal of Molecular Pathology</i> , 2021, 2, 109-113. | 0.5 | 2 |
| 207 | Intensive multidisciplinary treatment strategies and patient resilience to challenge long-term survival in metastatic colorectal cancer: a case report in real life and clinical practice. <i>Annals of Translational Medicine</i> , 2021, 9, 1027-1027. | 0.7 | 2 |
| 208 | Liquid biopsy analysis of ALK alterations from advanced NSCLC patients: The value of exosomal RNA cargo (ExoALK).. <i>Journal of Clinical Oncology</i> , 2017, 35, e20569-e20569. | 0.8 | 2 |
| 209 | BRCA1/2 NGS Somatic Testing in Clinical Practice: A Short Report. <i>Genes</i> , 2021, 12, 1917. | 1.0 | 2 |
| 210 | Comparison of two next-generation sequencing-based approaches for liquid biopsy analysis in patients with non-small cell lung cancer: a multicentre study. <i>Journal of Clinical Pathology</i> , 2023, 76, 206-210. | 1.0 | 2 |
| 211 | Molecular landscape and actionable alterations in a genomic-guided cancer clinical trial: First analysis of the ROME trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3087-3087. | 0.8 | 2 |
| 212 | RNA-based next-generation sequencing in non-small-cell lung cancer in a routine setting: an experience from an Italian referral center. <i>Personalized Medicine</i> , 2022, 19, 395-401. | 0.8 | 2 |
| 213 | Concomitant Rare KRAS and BRAF Mutations in Lung Adenocarcinoma: A Case Report. <i>Journal of Molecular Pathology</i> , 2020, 1, 36-42. | 0.5 | 1 |
| 214 | Parallel sequencing of a 50 genes panel in metastatic colorectal cancer (MCRC) patients (pts) treated with intensive first-line Flr-B/FOx triplet chemotherapy plus bevacizumab (BEV): Preliminary data and clinical outcome.. <i>Journal of Clinical Oncology</i> , 2017, 35, 644-644. | 0.8 | 1 |
| 215 | Second-line avelumab in platinum-treated non-small cell lung cancer patients: comment on the JAVELIN Lung 200 clinical trial. <i>Translational Cancer Research</i> , 2019, 8, S145-S148. | 0.4 | 1 |
| 216 | Differential clinical outcome of metastatic colorectal cancer (MCRC) patients (pts) treated with first line Flr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy according to KRAS, NRAS and BRAF genotype detected by massive parallel sequencing.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15041-e15041. | 0.8 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 217 | Analysis of Programmed Death-Ligand 1 Expression, Stromal Tumor-Infiltrating Lymphocytes, and Mismatch Repair Deficiency in Invasive Micropapillary Carcinoma of the Breast. <i>Journal of Immunotherapy and Precision Oncology</i> , 2019, 2, 130-136. | 0.6 | 1 |
| 218 | Tissue Microarray from Cell Block Material (cbTMA)â€”An Additional Shot for Cytology in the Predictive Pathology Era: The PD-L1 Experience. <i>Journal of Molecular Pathology</i> , 2022, 3, 15-23. | 0.5 | 1 |
| 219 | Predictive molecular pathology in metastatic thyroid cancer: the role of <i>RET</i> fusions. <i>Expert Review of Endocrinology and Metabolism</i> , 2022, 17, 167-178. | 1.2 | 1 |
| 220 | Microsatellite instability evaluation of patients with solid tumour: routine practice insight from a large series of Italian referral centre. <i>Journal of Clinical Pathology</i> , 2022, , jclinpath-2022-208203. | 1.0 | 1 |
| 221 | Fineâ€”needle aspiration findings in focal (nodular) myositis of a newborn: A case report. <i>Diagnostic Cytopathology</i> , 2015, 43, 920-923. | 0.5 | 0 |
| 222 | EGFR testing and the CAP/IASLC/AMP lung cancer biomarker testing guidelines: knowledge gaps and future directions. <i>Lung Cancer Management</i> , 2015, 4, 87-95. | 1.5 | 0 |
| 223 | Editorial: Second Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological and Molecular Aspects of Novel Promising Drugs. <i>Frontiers in Medicine</i> , 2017, 4, 63. | 1.2 | 0 |
| 224 | Differential clinical outcome according to KRAS, NRAS and BRAF genotype detected by massive parallel sequencing of metastatic colorectal cancer patients treated with first line Flr-B/FOx adding bevacizumab to triplet chemotherapy. <i>Annals of Oncology</i> , 2017, 28, iii95-iii96. | 0.6 | 0 |
| 225 | Mismatch repair proteins and microsatellite instability in solid pseudopapillary neoplasm of the pancreas. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2019, 18, 491-492. | 0.6 | 0 |
| 226 | Pathology in non-small cell lung cancer: evolving scenario. <i>Precision Cancer Medicine</i> , 2019, 2, 17-17. | 1.8 | 0 |
| 227 | Next-Generation Sequencing in Clinical Practice. , 2019, , 57-64. | | 0 |
| 228 | RNA-Based Assays. , 2019, , 99-119. | | 0 |
| 229 | Comparison between two different next generation sequencing platforms for clinical relevant gene mutation test in solid tumours. <i>Journal of Clinical Pathology</i> , 2020, 73, 602-604. | 1.0 | 0 |
| 230 | Liquid Biopsy: A New Diagnostic Strategy and Not Only for Lung Cancer?. , 0, , . | | 0 |
| 231 | Liquid Biopsy. UNIPA Springer Series, 2021, , 99-122. | 0.1 | 0 |
| 232 | Thyroid Carcinoma: Molecular Signature by Histotype-Specific Mutations and Gene Expression Patterns. , 2012, , 165-178. | | 0 |
| 233 | EGFR mutation detection on lung cancer cytological specimens by the rapid and fully integrated Idylla molecular diagnostics system.. <i>Journal of Clinical Oncology</i> , 2016, 34, e20542-e20542. | 0.8 | 0 |
| 234 | Fully automated PCR detection of KRAS mutations on pancreatic endoscopic ultrasound fine needle aspirates.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15726-e15726. | 0.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 235 | Clinical Practice Implications: Monitoring Drug Response and Resistance. <i>Current Clinical Pathology</i> , 2017, , 201-202. | 0.0 | 0 |
| 236 | How to Prepare Cytological Samples for Molecular Testing. , 2018, , 11-28. | | 0 |
| 237 | Listening understanding and acting (lung): focus on communicational issue in thoracic oncology. <i>Translational Cancer Research</i> , 2018, 8, S16-S22. | 0.4 | 0 |
| 238 | Targeted therapy and non-small cell lung cancer: a new era!. <i>Translational Cancer Research</i> , 2018, 8, S1-S2. | 0.4 | 0 |
| 239 | Intensive first line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in <i>RAS</i> wild-type metastatic colorectal cancer patients: Preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15517-e15517. | 0.8 | 0 |
| 240 | Opening New Boundaries in Biomarker Detection: Awakening of Middle East and North Africa Region. <i>Journal of Immunotherapy and Precision Oncology</i> , 2019, 2, 8-9. | 0.6 | 0 |
| 241 | Antithrombotics in idiopathic pulmonary fibrosis patients with concomitant antifibrotic therapy: a single centre real world experience. , 2020, , . | | 0 |
| 242 | “Depart from evil, and do good” turning Axl from uncontrolled tumorigenic gene to biomarker for early detection of pancreatic cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2022, , 103659. | 2.0 | 0 |
| 243 | Fine-Needle Aspiration Is Suitable for Breast Cancer BRCA Molecular Assessment: A Case Report. <i>Journal of Molecular Pathology</i> , 2021, 2, 319-324. | 0.5 | 0 |
| 244 | Editorial: Molecular Characterization of Thyroid Lesions in the Era of “Next-Generation” Techniques. <i>Frontiers in Endocrinology</i> , 0, 13, . | 1.5 | 0 |